{"schema_version":"secwatch.filing_event.v1","accession":"0001062822-26-000094","form_type":"8-K","ticker":"LXRX","cik":"0001062822","company_name":"LEXICON PHARMACEUTICALS, INC.","filed_at":"2026-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:31.894364+00:00","generated_at":"2026-05-14T22:27:19.400107+00:00","sec_items":["1.01","2.03","3.02","7.01","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Lexicon secures $100M loan facility from Hercules Capital; $55M funded at closing","bullets":["Initial $55M tranche drawn at closing to repay existing Oxford Finance loan; second $20M and third $25M tranches available subject to milestones.","Interest rate = prime + 3.10% with 9.85% floor; initial 18-month interest-only period extendable to 30 months upon achieving clinical/regulatory milestones.","Loan matures May 4, 2030; secured by first lien on all assets; minimum cash covenant starts June 1, 2027.","Hercules received warrants to buy 691,823 shares at $1.59 per share; additional warrants up to 566,037 shares upon future tranche draws.","Funds support Lexicon's late-stage cardiometabolic pipeline including sotagliflozin HCM trial and potential regulatory filings."],"urls":{"canonical":"https://secwatch.observer/filing/0001062822-26-000094","json":"https://secwatch.observer/filing/0001062822-26-000094.json","markdown":"https://secwatch.observer/filing/0001062822-26-000094.md","text":"https://secwatch.observer/filing/0001062822-26-000094.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000094/0001062822-26-000094-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000094/lxrx-20260504.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T22:27:19.400107+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"149edfb578accf5e88e4c346b388bca003e13f0c","claim":"LEXICON PHARMACEUTICALS, INC. incurred credit facility of up to $100 million in borrowing capacity with Hercules Capital, Inc. and certain of its affiliates at prime rate plus 3.10%, but not less than 9.85% maturing May 2030.","evidence_excerpt":"On May 4, 2026, Lexicon Pharmaceuticals, Inc. (\" Lexicon \") and its subsidiaries entered into a loan and security agreement with Hercules Capital, Inc. and certain of its affiliates (\" Hercules \") that provides up to $100 million in borrowing capacity (the \" Hercules Term Loans \") available in three tranches, each maturing in May 2030.","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000094/0001062822-26-000094-index.htm","confidence":1.0},{"claim_id":"43742554bb6608ff63d5b937339afda5ec688408","claim":"LEXICON PHARMACEUTICALS, INC. entered into Loan and Security Agreement with Hercules Capital, Inc. and certain of its affiliates valued at up to $100 million (effective 2026-05-04).","evidence_excerpt":"On May 4, 2026, Lexicon Pharmaceuticals, Inc. (“ Lexicon ”) and its subsidiaries entered into a loan and security agreement with Hercules Capital, Inc. and certain of its affiliates (“ Hercules ”) that provides up to $100 million in borrowing capacity","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000094/0001062822-26-000094-index.htm","confidence":0.9}],"comparable_filings":[{"accession":"0001213900-26-054183","ticker":"EMAT","company_name":"Evolution Metals & Technologies Corp.","filed_at":"2026-05-11T23:59:59+00:00","headline":"EMAT secures $100M convertible debenture facility from Yorkville; first $20M tranche issued","event_type":"debt","sec_items":["1.01","2.03","3.02","7.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: debt_financing, material_agreement","same SEC item: 1.01, 2.03, 3.02, 7.01, 9.01","same event type: debt","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-054183","json":"https://secwatch.observer/filing/0001213900-26-054183.json","markdown":"https://secwatch.observer/filing/0001213900-26-054183.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1866226/000121390026054183/0001213900-26-054183-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1866226/000121390026054183/ea0290073-8k_evolution.htm"},"side_by_side_evidence":{"fact_type":"debt_financing","source_excerpt":"On May 4, 2026, Lexicon Pharmaceuticals, Inc. (\" Lexicon \") and its subsidiaries entered into a loan and security agreement with Hercules Capital, Inc. and certain of its affiliates (\" Hercules \") that provides up to $100 million in borrowing capacity (the \" Hercules Term Loans \") available in three tranches, each maturing in May 2030.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000094/0001062822-26-000094-index.htm","comparable_excerpt":"The first Convertible Debenture (the “First Debenture”) in the principal amount of $20,000,000 was issued on May 7, 2026.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1866226/000121390026054183/0001213900-26-054183-index.htm"}},{"accession":"0001213900-26-053894","ticker":"TBH","company_name":"Brag House Holdings, Inc.","filed_at":"2026-05-08T23:59:59+00:00","headline":"Brag House issues $2.5M convertible notes at 25% OID; proceeds for House of Doge merger","event_type":"debt","sec_items":["1.01","2.03","3.02","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: debt_financing, material_agreement","same SEC item: 1.01, 2.03, 3.02, 9.01","same event type: debt","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-053894","json":"https://secwatch.observer/filing/0001213900-26-053894.json","markdown":"https://secwatch.observer/filing/0001213900-26-053894.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1903595/000121390026053894/0001213900-26-053894-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1903595/000121390026053894/ea0289773-8k_braghouse.htm"},"side_by_side_evidence":{"fact_type":"debt_financing","source_excerpt":"On May 4, 2026, Lexicon Pharmaceuticals, Inc. (\" Lexicon \") and its subsidiaries entered into a loan and security agreement with Hercules Capital, Inc. and certain of its affiliates (\" Hercules \") that provides up to $100 million in borrowing capacity (the \" Hercules Term Loans \") available in three tranches, each maturing in May 2030.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000094/0001062822-26-000094-index.htm","comparable_excerpt":"The issuance of the Notes in the aggregate original principal amount of $2,500,000 constitutes the creation of a direct financial obligation of the Company. The Notes bear interest at 12.0% per annum, mature on February 4, 2027","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1903595/000121390026053894/0001213900-26-053894-index.htm"}},{"accession":"0001492691-26-000042","ticker":"KNX","company_name":"Knight-Swift Transportation Holdings Inc.","filed_at":"2026-05-08T23:59:59+00:00","headline":"Knight-Swift closes $1.5B convertible note offering at 1.00% due 2031; proceeds used to repay term loans and revolver","event_type":"debt","sec_items":["1.01","2.03","3.02","8.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: debt_financing, material_agreement","same SEC item: 1.01, 2.03, 3.02, 9.01","same event type: debt","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001492691-26-000042","json":"https://secwatch.observer/filing/0001492691-26-000042.json","markdown":"https://secwatch.observer/filing/0001492691-26-000042.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1492691/000149269126000042/0001492691-26-000042-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1492691/000149269126000042/knx-20260505.htm"},"side_by_side_evidence":{"fact_type":"debt_financing","source_excerpt":"On May 4, 2026, Lexicon Pharmaceuticals, Inc. (\" Lexicon \") and its subsidiaries entered into a loan and security agreement with Hercules Capital, Inc. and certain of its affiliates (\" Hercules \") that provides up to $100 million in borrowing capacity (the \" Hercules Term Loans \") available in three tranches, each maturing in May 2030.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000094/0001062822-26-000094-index.htm","comparable_excerpt":"On May 8, 2026, Knight-Swift Transportation Holdings Inc. (the \"Company\") completed its previously announced private offering (the \"Offering\") of $1.5 billion aggregate principal amount of 1.00% Convertible Senior Notes due 2031","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1492691/000149269126000042/0001492691-26-000042-index.htm"}},{"accession":"0001104659-26-057128","ticker":"PUMP","company_name":"ProPetro Holding Corp.","filed_at":"2026-05-07T23:59:59+00:00","headline":"ProPetro issues $690M zero-coupon convertible notes due 2031, expands credit facility","event_type":"debt","sec_items":["1.01","2.03","3.02","8.01","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same fact type: debt_financing, material_agreement","same SEC item: 1.01, 2.03, 3.02, 9.01","same event type: debt","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-057128","json":"https://secwatch.observer/filing/0001104659-26-057128.json","markdown":"https://secwatch.observer/filing/0001104659-26-057128.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1680247/000110465926057128/0001104659-26-057128-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1680247/000110465926057128/tm2613899d1_8k.htm"},"side_by_side_evidence":{"fact_type":"debt_financing","source_excerpt":"On May 4, 2026, Lexicon Pharmaceuticals, Inc. (\" Lexicon \") and its subsidiaries entered into a loan and security agreement with Hercules Capital, Inc. and certain of its affiliates (\" Hercules \") that provides up to $100 million in borrowing capacity (the \" Hercules Term Loans \") available in three tranches, each maturing in May 2030.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000094/0001062822-26-000094-index.htm","comparable_excerpt":"On May 7, 2026, ProPetro Holding Corp. (the “ Company ”), issued $690 million aggregate principal amount of its 0.00% Convertible Senior Notes due 2031","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1680247/000110465926057128/0001104659-26-057128-index.htm"}},{"accession":"0001104659-26-057138","ticker":"OCGN","company_name":"Ocugen, Inc.","filed_at":"2026-05-07T23:59:59+00:00","headline":"Ocugen completes $115M convertible note offering at 6.75%, repays Avenue loan","event_type":"debt","sec_items":["1.01","1.02","2.02","2.03","3.02","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: debt_financing, material_agreement","same SEC item: 1.01, 2.03, 3.02, 9.01","same event type: debt","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-057138","json":"https://secwatch.observer/filing/0001104659-26-057138.json","markdown":"https://secwatch.observer/filing/0001104659-26-057138.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1372299/000110465926057138/0001104659-26-057138-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1372299/000110465926057138/tm2613898d1_8k.htm"},"side_by_side_evidence":{"fact_type":"debt_financing","source_excerpt":"On May 4, 2026, Lexicon Pharmaceuticals, Inc. (\" Lexicon \") and its subsidiaries entered into a loan and security agreement with Hercules Capital, Inc. and certain of its affiliates (\" Hercules \") that provides up to $100 million in borrowing capacity (the \" Hercules Term Loans \") available in three tranches, each maturing in May 2030.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000094/0001062822-26-000094-index.htm","comparable_excerpt":"On May 7, 2026, Ocugen, Inc. (the “Company”) completed its previously announced private offering (the “offering”) of $115.0 million aggregate principal amount of 6.75% Convertible Senior Notes due 2034 (the “notes”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1372299/000110465926057138/0001104659-26-057138-index.htm"}},{"accession":"0001193125-26-212391","ticker":"RNST","company_name":"RENASANT CORP","filed_at":"2026-05-07T23:59:59+00:00","headline":"Renasant prices $300M 6.25% sub notes due 2036, net $295.7M, may redeem $40M 5.50% notes","event_type":"debt","sec_items":["1.01","2.03","7.01","9.01"],"materiality_score":0.55,"calibrated_materiality_score":0.55,"match_reasons":["same fact type: debt_financing, material_agreement","same SEC item: 1.01, 2.03, 7.01, 9.01","same event type: debt","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-212391","json":"https://secwatch.observer/filing/0001193125-26-212391.json","markdown":"https://secwatch.observer/filing/0001193125-26-212391.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/715072/000119312526212391/0001193125-26-212391-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/715072/000119312526212391/d145081d8k.htm"},"side_by_side_evidence":{"fact_type":"debt_financing","source_excerpt":"On May 4, 2026, Lexicon Pharmaceuticals, Inc. (\" Lexicon \") and its subsidiaries entered into a loan and security agreement with Hercules Capital, Inc. and certain of its affiliates (\" Hercules \") that provides up to $100 million in borrowing capacity (the \" Hercules Term Loans \") available in three tranches, each maturing in May 2030.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000094/0001062822-26-000094-index.htm","comparable_excerpt":"for the issuance and sale of $300 million aggregate principal amount of its 6.25% Fixed-to-Floating Rate Subordinated Notes due 2036","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/715072/000119312526212391/0001193125-26-212391-index.htm"}},{"accession":"0001360604-26-000047","ticker":"HR","company_name":"Healthcare Realty Trust Inc","filed_at":"2026-05-07T23:59:59+00:00","headline":"HR subsidiary issues $700M 3.00% exchangeable senior notes due 2032","event_type":"debt","sec_items":["1.01","2.03","3.02","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: debt_financing, material_agreement","same SEC item: 1.01, 2.03, 3.02, 9.01","same event type: debt","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001360604-26-000047","json":"https://secwatch.observer/filing/0001360604-26-000047.json","markdown":"https://secwatch.observer/filing/0001360604-26-000047.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1360604/000136060426000047/0001360604-26-000047-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1360604/000136060426000047/hr-20260507.htm"},"side_by_side_evidence":{"fact_type":"debt_financing","source_excerpt":"On May 4, 2026, Lexicon Pharmaceuticals, Inc. (\" Lexicon \") and its subsidiaries entered into a loan and security agreement with Hercules Capital, Inc. and certain of its affiliates (\" Hercules \") that provides up to $100 million in borrowing capacity (the \" Hercules Term Loans \") available in three tranches, each maturing in May 2030.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000094/0001062822-26-000094-index.htm","comparable_excerpt":"issued $700,000,000 aggregate principal amount of its 3.00% Exchangeable Senior Notes due 2032","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1360604/000136060426000047/0001360604-26-000047-index.htm"}},{"accession":"0001140361-26-023577","ticker":"TCPC","company_name":"BlackRock TCP Capital Corp.","filed_at":"2026-06-01T20:50:02+00:00","headline":"BlackRock TCP Capital closes $535.8M CLO securitization, repays existing debt facilities","event_type":"debt","sec_items":["1.01","1.02","2.03","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: debt_financing, material_agreement","same SEC item: 1.01, 2.03, 9.01","same event type: debt","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-023577","json":"https://secwatch.observer/filing/0001140361-26-023577.json","markdown":"https://secwatch.observer/filing/0001140361-26-023577.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1370755/000114036126023577/0001140361-26-023577-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1370755/000114036126023577/ef20075169_8k.htm"},"side_by_side_evidence":{"fact_type":"debt_financing","source_excerpt":"On May 4, 2026, Lexicon Pharmaceuticals, Inc. (\" Lexicon \") and its subsidiaries entered into a loan and security agreement with Hercules Capital, Inc. and certain of its affiliates (\" Hercules \") that provides up to $100 million in borrowing capacity (the \" Hercules Term Loans \") available in three tranches, each maturing in May 2030.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000094/0001062822-26-000094-index.htm","comparable_excerpt":"Item 1.01. Entry into a Material Definitive Agreement. On May 27, 2026 (the \" Closing Date \"), BlackRock TCP Capital Corp. (the \" Company \"), through its subsidiary, completed a $535,780,000 securitization of certain loans held by a subsidiary of the Company (the \" CLO Transaction \"). On the Closing Date and in connection with the CLO Transaction, BlackRock DLF 2026-C","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1370755/000114036126023577/0001140361-26-023577-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}